Care
The company will use the funds to advance its brain shuttle platform that delivers RNAi therapies across the blood-brain barrier to help treat neurodegenerative diseases.
The pharma giant alleges that Hims & Hers is infringing its patents and misleading consumers by selling unsafe, unapproved compounded versions of its semaglutide drugs.
HHS is looking at how the care plan is supporting the patient, says Sandy Griffiths, senior product manager for Homecare Homebase.
CEO of Lirio, Marten den Haring, explains how the company uses its proprietary Large Behavior Model to understand a person’s health behaviors, motivations and decision-making patterns to drive personalized patient engagement in healthcare.
Also, Omniscient Neurotechnology has received $14 million in government-backed funding to scale its AI-based brain mapping platform.
Patients can see the discounted prices on TrumpRx.gov, but the site does not currently sell the drugs.
The company has filed to list its Class A shares as it looks to scale its AI- and blockchain-enabled telehealth platform after U.S. expansion and private financing.
Emerging Technologies
Sergio Calvo, general manager of theranostics at GE HealthCare, joins MobiHealthNews to discuss how combining molecular imaging and targeted therapy is personalizing cancer care.
Emerging Technologies
Sergio Calvo, general manager of theranostics at GE HealthCare, discusses the organization's use of theranostics in cancer care and how the technology combines targeted therapy with diagnostic imaging for personalized oncology care.
As medical practices seek to implement agentic AI, Michael Clark, OnPoint Healthcare Partners president, recommends constant oversight to ensure agents' work is repeatable, auditable and traceable by a clinical advisory team.